Announcement Details

View all announcements

Total Voting Rights

Hemogenyx Pharmaceuticals plc

(“Hemogenyx” or the “Company”)

 

Total Voting Rights

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company consists of 397,921,969 ordinary shares of 1 penny each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 397,921,969.

The figure of 397,921,969 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

 

Enquiries:

Hemogenyx Pharmaceuticals plc hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Capital Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
US Media enquiries Tel: +1 (323) 646-3249
Lowell Goodman lowell@corbomitecomms.com

 

View all announcements